Scholar Rock (NASDAQ:SRRK) COO Keith Woods Sells 10,220 Shares

Scholar Rock Holding Corporation (NASDAQ:SRRK) COO Keith Woods sold 10,220 shares of the company’s stock in a transaction dated Thursday, April 16th. The shares were sold at an average price of $49.57, for a total transaction of $506,605.40. Following the transaction, the chief operating officer directly owned 620,055 shares of the company’s stock, valued at $30,736,126.35. This represents a 1.62% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Scholar Rock Stock Performance

SRRK traded down $2.16 on Monday, hitting $47.80. 1,128,695 shares of the stock traded hands, compared to its average volume of 1,353,022. The business has a fifty day moving average price of $46.16 and a two-hundred day moving average price of $42.03. The company has a current ratio of 6.95, a quick ratio of 6.95 and a debt-to-equity ratio of 0.41. Scholar Rock Holding Corporation has a 52 week low of $27.07 and a 52 week high of $51.63. The firm has a market capitalization of $5.49 billion, a PE ratio of -13.94 and a beta of 0.68.

Scholar Rock (NASDAQ:SRRK) last issued its earnings results on Tuesday, March 3rd. The company reported ($0.76) EPS for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.10. During the same period last year, the business earned ($0.64) earnings per share. On average, research analysts predict that Scholar Rock Holding Corporation will post -3.13 EPS for the current fiscal year.

Institutional Trading of Scholar Rock

Large investors have recently added to or reduced their stakes in the company. IFP Advisors Inc raised its stake in shares of Scholar Rock by 294.1% in the fourth quarter. IFP Advisors Inc now owns 603 shares of the company’s stock valued at $27,000 after acquiring an additional 450 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Scholar Rock in the fourth quarter valued at $30,000. Summit Securities Group LLC acquired a new position in Scholar Rock during the 4th quarter worth about $31,000. Ramirez Asset Management Inc. acquired a new stake in Scholar Rock in the 3rd quarter valued at about $37,000. Finally, EverSource Wealth Advisors LLC lifted its position in shares of Scholar Rock by 151.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 872 shares of the company’s stock worth $38,000 after purchasing an additional 525 shares in the last quarter. 91.08% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. Citigroup lifted their target price on shares of Scholar Rock from $55.00 to $58.00 and gave the company a “buy” rating in a research report on Wednesday, March 4th. BMO Capital Markets raised their price target on shares of Scholar Rock from $50.00 to $70.00 and gave the stock an “outperform” rating in a research note on Wednesday, March 4th. UBS Group assumed coverage on Scholar Rock in a report on Wednesday, January 7th. They set a “buy” rating and a $60.00 price objective on the stock. Truist Financial upped their price objective on Scholar Rock from $44.00 to $55.00 and gave the company a “buy” rating in a research note on Tuesday, March 3rd. Finally, Piper Sandler raised their target price on Scholar Rock from $51.00 to $58.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 4th. Four analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Scholar Rock presently has an average rating of “Buy” and a consensus target price of $55.40.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).